PDRN in Atopic Dermatitis: Anti-Inflammatory Mechanisms and Clinical Evidence (2020)

Key Findings

• PDRN significantly reduces clinical severity scores, scratching behavior, epidermal hyperplasia, and mast cell infiltration in a DNCB-induced mouse model of atopic dermatitis, with effects mediated through the adenosine A2A receptor ^[2].
• A2A receptor activation by PDRN suppresses Th2-dominant cytokines central to AD pathogenesis, including IL-4, IL-13, IL-31, and TNF-alpha, through inhibition of the NF-kB signaling cascade ^[1][2].
• PDRN's nucleotide salvage pathway activity provides deoxyribonucleotide substrates that support keratinocyte proliferation and differentiation, contributing to epidermal barrier restoration in barrier-compromised skin ^[3][4].
• Preclinical evidence supports PDRN as a potential adjunctive therapy in atopic dermatitis management, with a favorable safety profile that distinguishes it from immunosuppressive agents ^[1][2][4].
• The dual mechanism of action — receptor-mediated anti-inflammatory signaling combined with metabolic barrier repair support — positions PDRN as a uniquely relevant candidate for AD, a disease defined by the convergence of immune dysregulation and barrier dysfunction ^[2][3].

Background

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease affecting approximately 15-20% of children and 2-10% of adults worldwide, with prevalence increasing substantially in industrialized nations over the past several decades ^[6]. The disease imposes a significant burden on quality of life through persistent pruritus, sleep disruption, and psychosocial distress, and its management remains a major clinical challenge in dermatology ^[6].

The pathophysiology of AD is characterized by three interconnected pillars: immune dysregulation with Th2-dominant inflammation, epidermal barrier dysfunction, and a self-perpetuating itch-scratch cycle ^[6]. In the acute phase, activated Th2 lymphocytes release IL-4, IL-13, IL-5, and IL-31, which drive IgE overproduction, eosinophil recruitment, and direct stimulation of sensory nerve fibers responsible for pruritus ^[6]. IL-4 and IL-13 further impair barrier function by downregulating filaggrin expression and disrupting the synthesis of ceramides and other intercellular lipids essential for the stratum corneum's permeability barrier ^[6]. This barrier compromise increases transepidermal water loss (TEWL), facilitates allergen and microbial penetration, and perpetuates the inflammatory response in a vicious cycle ^[6]. TNF-alpha, produced by activated mast cells and macrophages in AD lesional skin, amplifies the inflammatory milieu and contributes to epidermal spongiosis and hyperplasia ^[2][6].

Current AD treatment relies primarily on topical corticosteroids, calcineurin inhibitors, and, in moderate-to-severe cases, systemic immunosuppressants or biologics such as dupilumab ^[6]. While effective, these therapies carry limitations including skin atrophy with prolonged corticosteroid use, potential immunosuppression-related adverse events, and high cost for biologic agents ^[6]. This therapeutic landscape has generated interest in novel agents that can address both the inflammatory and barrier-repair dimensions of AD with an improved safety profile. PDRN, a mixture of deoxyribonucleotide polymers (50-1500 kDa) derived from Oncorhynchus mykiss, has emerged as a candidate of interest due to its dual mechanism encompassing anti-inflammatory A2A receptor agonism and nucleotide salvage pathway-mediated tissue repair support ^[1][4].

Mechanism of Action

PDRN's relevance to atopic dermatitis is grounded in its pharmacological activity at the adenosine A2A receptor and its parallel function as a substrate for the nucleotide salvage pathway — two mechanisms that address distinct but complementary aspects of AD pathology ^[1][4].

A2A receptor-mediated cytokine suppression. PDRN binds specifically to the adenosine A2A receptor expressed on keratinocytes, fibroblasts, mast cells, macrophages, and T lymphocytes ^[1]. Receptor activation triggers the adenylate cyclase-cAMP-PKA signaling cascade, which inhibits NF-kB nuclear translocation and thereby suppresses transcription of pro-inflammatory cytokines ^[1][2]. In the context of AD, this mechanism is particularly significant because NF-kB is a master regulator of the Th2 cytokine program: its inhibition reduces production of IL-4, IL-13, IL-31, and TNF-alpha — the cytokines most directly implicated in AD flare severity, pruritus intensity, and barrier gene downregulation ^[2][6]. Additionally, A2A receptor activation on mast cells stabilizes these cells against degranulation, reducing histamine and tryptase release that contribute to acute pruritus and vascular permeability in AD lesions ^[1][2]. The specificity of this mechanism has been validated pharmacologically through studies using the selective A2A receptor antagonist ZM241385, which abolishes PDRN's anti-inflammatory effects ^[1][2].

Nucleotide salvage pathway and barrier support. Independent of its receptor activity, PDRN is enzymatically degraded to individual deoxyribonucleotides and nucleosides that enter the salvage pathway, bypassing the energy-intensive de novo nucleotide synthesis that is often rate-limited in rapidly proliferating or metabolically stressed tissues ^[3][4]. In AD-affected skin, where barrier turnover is accelerated and keratinocyte differentiation is disordered, this exogenous nucleotide supply supports normalized keratinocyte proliferation and terminal differentiation — processes essential for restoring filaggrin expression, lamellar body formation, and the lipid-matrix organization of the stratum corneum ^[3][4][5]. By supporting these structural elements of barrier competence, PDRN may contribute to reducing TEWL and restoring the skin's resistance to environmental allergen and irritant penetration ^[3][4].

Preclinical Evidence

The most directly relevant preclinical study is the 2020 investigation by Irrera et al. published in Biomedicines, which evaluated PDRN's effects in a well-established 2,4-dinitrochlorobenzene (DNCB)-induced murine model of atopic dermatitis ^[2].

Study design. BALB/c mice were sensitized and repeatedly challenged with DNCB to induce AD-like dermatitis on dorsal skin. Animals were randomized to receive PDRN (8 mg/kg intraperitoneally) or vehicle control for the duration of the challenge period. Disease severity was assessed using a modified SCORAD (Scoring Atopic Dermatitis) index adapted for murine models, and scratching behavior was quantified through direct observation. Skin specimens were evaluated histologically for epidermal thickness, spongiosis, and inflammatory cell infiltration, with particular attention to mast cell counts via toluidine blue staining ^[2].

Clinical and behavioral outcomes. PDRN-treated mice demonstrated significantly lower SCORAD scores compared to vehicle-treated controls, with visible reductions in erythema, edema, excoriation, and scaling on challenged skin ^[2]. Scratching frequency — a behavioral correlate of pruritus — was markedly reduced in the PDRN group, suggesting attenuation of the itch-scratch cycle that perpetuates AD chronicity ^[2].

Histopathological findings. Histological analysis revealed that PDRN treatment substantially reduced epidermal hyperplasia (acanthosis) compared to untreated AD controls, with epidermal thickness approaching values observed in non-sensitized normal skin ^[2]. Mast cell infiltration in the upper dermis was significantly diminished, consistent with PDRN's known mast cell-stabilizing activity through A2A receptor engagement ^[1][2]. The reduction in mast cell density correlated with diminished pruritus-related scratching behavior, supporting a mechanistic link between PDRN's cellular effects and its clinical impact on itch ^[2].

Cytokine and molecular analysis. PDRN treatment significantly reduced tissue levels of key AD-associated inflammatory mediators including TNF-alpha and Th2 cytokines ^[2]. NF-kB activation was attenuated in the PDRN-treated group, providing direct molecular confirmation of the A2A-cAMP-PKA-NF-kB signaling pathway as the operative mechanism in this disease model ^[2]. These cytokine reductions were consistent with findings from PDRN studies in other inflammatory models, including collagen-induced arthritis and diabetic wound healing, reinforcing the generalizability of the A2A-mediated anti-inflammatory mechanism across tissue contexts ^[1][5].

Clinical Implications

The preclinical evidence from the DNCB mouse model provides a biologically coherent rationale for investigating PDRN as an adjunctive therapy in atopic dermatitis management ^[2]. Several features of PDRN's pharmacological profile are particularly relevant to the clinical AD context.

Complementarity with existing therapies. PDRN's mechanism of action — A2A receptor-mediated NF-kB suppression — is pharmacologically distinct from the mechanisms of topical corticosteroids (glucocorticoid receptor-mediated transcriptional regulation), calcineurin inhibitors (calcineurin-NFAT pathway blockade), and dupilumab (IL-4R-alpha blockade) ^[1][6]. This mechanistic orthogonality suggests that PDRN could serve as an adjunctive agent that complements rather than duplicates existing therapies, potentially allowing dose reduction of corticosteroids or calcineurin inhibitors when used in combination ^[1][2].

Topical PDRN for barrier support. The growing availability of topical PDRN formulations in the cosmeceutical market — including creams, serums, and ampoules — presents a practical vehicle for delivering PDRN's barrier-supportive nucleotide supply directly to AD-affected skin ^[3][4]. Topical application avoids systemic exposure while concentrating the nucleotide salvage substrate at the site of barrier compromise, where keratinocyte turnover is most accelerated ^[3]. Products containing PDRN in combination with ceramides or centella asiatica-derived actives may offer particular relevance for AD patients seeking non-steroidal maintenance therapy during remission phases ^[3][4].

Safety profile considerations. PDRN has demonstrated an excellent safety profile across its documented clinical applications, with no reported immunogenic, mutagenic, or carcinogenic effects ^[1][4]. The purification process eliminates proteins and peptides from the source material, substantially reducing the risk of allergic sensitization — a critical consideration for AD patients who are predisposed to allergic responses ^[1][4]. This favorable safety profile contrasts with the well-documented adverse effect profiles of topical corticosteroids (skin atrophy, telangiectasia, adrenal suppression with prolonged use) and systemic immunosuppressants (infection risk, organ toxicity) ^[6].

Limitations and Future Directions

Several important limitations must be acknowledged when interpreting the current evidence for PDRN in atopic dermatitis.

The preclinical evidence, while mechanistically robust, derives primarily from a single murine AD model using DNCB sensitization ^[2]. While the DNCB model reproduces key features of human AD (Th2 inflammation, barrier disruption, pruritus), it does not fully recapitulate the chronic relapsing course, the genetic filaggrin loss-of-function mutations, or the complex microbial dysbiosis (Staphylococcus aureus colonization) that characterize human AD ^[2][6]. Translation from murine models to human disease requires caution, and the preclinical findings should be regarded as hypothesis-generating rather than definitive ^[2].

No randomized controlled trials have yet evaluated PDRN specifically in human atopic dermatitis patients ^[2]. The clinical evidence for PDRN's anti-inflammatory and tissue repair effects derives from wound healing, skin rejuvenation, and orthopedic contexts, where efficacy has been more extensively documented ^[1][4][5]. While the A2A receptor mechanism is conserved across these applications, disease-specific factors in AD — including the unique Th2 cytokine milieu, the role of IgE-mediated sensitization, and the contribution of filaggrin deficiency — may modulate PDRN's effectiveness in ways not captured by existing data ^[6].

The optimal delivery route, dosing regimen, and formulation for PDRN in AD remain undefined ^[2][3]. The preclinical study employed intraperitoneal injection, which is not clinically practical for a chronic skin condition ^[2]. Whether topical PDRN formulations achieve sufficient epidermal and dermal penetration to activate A2A receptors and supply the nucleotide salvage pathway at therapeutically relevant concentrations is an open question that requires pharmacokinetic investigation ^[3].

Future research priorities include: (1) well-designed, randomized, placebo-controlled trials evaluating topical PDRN in mild-to-moderate AD patients, with validated endpoints including EASI score, TEWL measurement, and patient-reported pruritus outcomes; (2) head-to-head or combination studies comparing PDRN with established topical agents; (3) bioavailability studies characterizing topical PDRN penetration in barrier-compromised AD skin versus intact skin; and (4) longer-term studies assessing PDRN's potential role in maintaining remission and reducing flare frequency ^[2][3][4].

Conclusion

The available evidence establishes a biologically plausible and mechanistically coherent rationale for PDRN's therapeutic potential in atopic dermatitis ^[1][2][3]. PDRN's dual mechanism — A2A receptor-mediated suppression of Th2 cytokines and NF-kB-driven inflammation, combined with nucleotide salvage pathway support for epidermal barrier repair — directly addresses the two central pathological axes of AD: immune dysregulation and barrier dysfunction ^[1][2][4][6]. The 2020 preclinical study by Irrera et al. provides compelling evidence that PDRN reduces clinical severity, pruritus, epidermal hyperplasia, and mast cell infiltration in a validated AD mouse model ^[2]. However, the evidence remains at the preclinical stage for the specific indication of atopic dermatitis, and translation to clinical practice requires human trials with rigorous methodology and disease-specific endpoints ^[2]. Given PDRN's favorable safety profile and mechanistic alignment with AD pathophysiology, it represents a promising candidate for further clinical investigation as an adjunctive or maintenance therapy in atopic dermatitis management ^[1][2][3][4].